TargetBeta
EZH2
enhancer of zeste 2 polycomb repressive complex 2 subunit · also EZH1, ENX-1, KMT6, KMT6A · Histone lysine methyltransferases
6 programs in company-led studies act on EZH2, from 6 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| zeprumetostatrule | Jiangsu HengRui Medicine | phase 3 | 177 running | – | NCIt |
| mevrometostat | Pfizer | phase 3 | 74 running | – | the company's pipeline |
| TR115rule | Tarapeutics Science | phase 3 | 33 running | – | the studies' text |
| tulmimetostat | Novartis | phase 2 | 33 running | EZH1 | the company's pipeline |
| EZH1/2 Inhibitor HH2853rule | Haihe Biopharma | phase 2 | 22 running | EZH1 | NCIt |
| valemetostatrule | Daiichi Sankyo | phase 1 | 11 running | EZH1 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Prostatic Neoplasms, 4 programs
- Bulbo-Spinal Atrophy, X-Linked, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Endometrial Neoplasms, 1 program
- Lymphoma, 1 program
- Lymphoma, Extranodal NK-T-Cell, 1 program
- Lymphoma, Follicular, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Lymphoma, T-Cell, Peripheral, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 28, 2027mevrometostat · Pfizer · phase 3 · NCT06551324
- Apr 2027zeprumetostat · Jiangsu HengRui Medicine · phase 3 · NCT06368167
- Dec 31, 2027EZH1/2 Inhibitor HH2853 · Haihe Biopharma · phase 2 · NCT04390737
- Jan 31, 2028valemetostat · Daiichi Sankyo · phase 1 · NCT07244341
- May 1, 2028TR115 · Tarapeutics Science · phase 3 · NCT07793318
- Nov 9, 2029tulmimetostat · Novartis · phase 2 · NCT07206056
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.